Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Hiroshi Iwamoto

1PUBLICATIONS

9CO-AUTHORS

Predictive and prognostic markers

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Dec 05, 2025

Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib.

Kei Kagawa, Takeshi Masuda, Kiyofumi Shimoji

Pageof 1

Frequent Collaborators

1 joint publications

Kei Kagawa

1 joint publications

Takeshi Masuda

1 joint publications

Kiyofumi Shimoji

1 joint publications

Kakuhiro Yamaguchi

1 joint publications

Shinjiro Sakamoto

1 joint publications

Yasushi Horimasu

1 joint publications

Taku Nakashima

1 joint publications

Hironobu Hamada

1 joint publications

Noboru Hattori

Frequent Collaborators

1 joint publications

Kei Kagawa

1 joint publications

Takeshi Masuda

1 joint publications

Kiyofumi Shimoji

1 joint publications

Kakuhiro Yamaguchi

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos